Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

California judge sets August 20 hearing in Allergan vs. Valeant case

Published 08/08/2014, 03:21 PM
Updated 08/08/2014, 03:21 PM
California judge sets August 20 hearing in Allergan vs. Valeant case

California judge sets August 20 hearing in Allergan vs. Valeant case

(Reuters) - The federal judge in California overseeing Allergan Inc's (N:AGN) insider trading lawsuit against Valeant Pharmaceuticals (TO:VRX) and activist investor William Ackman has set an Aug. 20 hearing date to decide on a fast-track schedule for the case, according to court documents.

Allergan, fighting a hostile takeover by Valeant and Ackman's Pershing Square Capital Management hedge fund, filed the lawsuit on Aug. 1. The Botox maker said in the complaint that Valeant and Ackman violated securities laws on tender offers when they teamed up on a $48 billion cash and stock offer.

The case could have implications for efforts by Pershing Square, which owns nearly 10 percent of Allergan's shares, and Valeant to call and hold a meeting of Allergan shareholders to vote in new board members.

Under Allergan's bylaws, Ackman needs 25 percent of shareholders to ask the company to call a meeting. Pershing Square has been gathering investor support and has said that it plans to submit the request in mid-August.

Those bylaws also say that Allergan cannot accept a special meeting request if there is a violation of securities rules, such as insider trading.

Ackman and Valeant offered to buy Allergan on April 22 and laid out a plan for spending cuts at the company. It later launched a hostile tender offer for its shares.

Allergan has mounted a defense that includes its own cost-cutting plans, and has urged shareholders not to support the meeting or the deal.

© Reuters. The head offices of Valeant Pharmaceuticals International Inc. are seen in Laval, Quebec

Judge David Carter in U.S. District Court, Central District of California, said in the documents that he would consider Allergan's request for an expedited schedule at a hearing rather than outside of "normal procedures," as requested.

(Reporting by Caroline Humer; Editing by Jonathan Oatis)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.